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ABSTRACT
Drug-resistant variants of HIV-1 reverse transcrip-
tase (RT) are also known to be resistant to anti-RT
RNA aptamers. In order to be able to develop diag-
nostics and therapies that can focus on otherwise
drug-resistant viruses, we have isolated two apta-
mers against a well-known, drug-resistant HIV-1 RT,
Mutant 3 (M3) from the multidrug-resistant HIV-1
RT panel. One aptamer, M302, bound M3 but
showed no significant affinity for wild-type (WT)
HIV-1 RT, while another aptamer, 12.01, bound
to both M3 and WT HIV-1 RTs. In contrast to
all previously selected anti-RT aptamers, neither
of these aptamers showed observable inhibition of
either polymerase or RNase H activities. Aptamers
M302 and 12.01 competed with one another for
binding to M3, but they did not compete with a pseu-
doknot aptamer for binding to the template/primer
cleft of WT HIV-1 RT. These results represent the
surprising identification of an additional RNA-bind-
ing epitope on the surface of HIV-1 RT. M3 and WT
HIV-1 RTs could be distinguished using an aptamer-
based microarray. By probing protein
conformation as a correlate to drug resistance we
introduce an additional and useful measure for
determining HIV-1 drug resistance.
INTRODUCTION
HIV-1 RT is a primary target in the generally accepted
highly active antiretroviral therapies (HAARTs) used in
the treatment of AIDS (1). Twelve of 25 anti-HIV drugs
approved by the FDA inhibit the DNA polymerase activ-
ity of HIV-1 reverse transcriptase (RT). These drugs can
be further classiﬁed as nucleoside analog RT inhibitors
(NRTI) and non-nucleoside RT inhibitors (NNRTI).
The NRTI drugs lack 30-hydroxyl moieties and function
as DNA chain terminators, while the NNRTI drugs
allosterically inhibit RT polymerase activity. In
HAART, multiple anti-HIV drugs including both NRTI
and NNRTI drugs are used in order to reduce the prob-
ability of the evolution of viral resistance.
However, drug resistance mutations that can inactivate
many of the anti-RT compounds are still found to arise
regularly (2), primarily because the process of reverse tran-
scription involves no proofreading mechanism. The muta-
tion rate of HIV-1 RT has been determined to be
3.4 10
–5 per nucleotide per replication cycle (3). Con-
sidering that  10 billion (10
10) HIV-1 virions are pro-
duced daily in an infected individual (4), viruses with
almost every possible single mutation as well as most of
the double mutations are expected to be readily generated.
The development of drug-resistant viruses in patients
quickly leads to the failure of HAART (5). Indeed, the
proportion of drug-resistant strains in new HIV-1 infec-
tions detected by sequence analysis rose from 8.0% in
1995–98 to 22.7% in 1999–2000 in North America (6). It
was similarly reported that the prevalence of the transmis-
sion of drug-resistant HIV-1 rose from 13.2% in 1995–98
to 24.1% in 2003–04 in New York City (7). With the
increasing prevalence of drug resistance, it is of great
necessity to develop both new antiretroviral drugs that
can target mutant HIV-1 RTs and also low-cost diagnostic
assays capable of identifying drug-resistant forms of HIV-
1 RT and thereby guiding therapies.
Aptamers are nucleic acid-binding species selected
in vitro, and have proven to be as good as monoclonal
antibodies for distinguishing between protein targets.
In particular, numerous RNA and DNA aptamers have
been isolated that target wild-type (WT) HIV-1 RT (8).
The ﬁrst HIV-1 RT aptamer was isolated in the Gold lab
from an RNA pool that spanned a 32-nt random region
(9). The selected aptamers folded into a pseudoknot struc-
ture and bound RT with dissociation constants in the low
nanomolar range. Additional RNA aptamers against WT
HIV-1 RT have since been selected from N70 and N80
pools (10). These aptamers formed either pseudoknot or
stem–loop structures, and again bound WT HIV-1 RT in
the low nanomolar range. DNA aptamers against HIV-1
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pseudoknots (11) and G-quartets (12).
While WT HIV-1 RT is bound by these aptamers, little
was known about how anti-RT aptamers interacted with
drug-resistant RT variants. Pseudoknot-like anti-RT
RNA aptamers expressed in vivo have been shown to be
eﬀective against HIV-1 subtypes A, B, D, E and F, but
more poorly inhibited subtypes C and O and the chimera
A/D (13). The RNA aptamers shown to inhibit HIV
strains were known to be resistant to AZT, 3TC, ddI,
ddC and nevirapine. However, the binding properties of
the aptamers in vitro were unknown, as was the correla-
tion between binding in vitro and activity in vivo. More
recent studies have shown that DNA anti-RT aptamers
can inhibit an even broader range of RT variants in vitro
(including HIV-1, HIV-2 and simian immunodeﬁciency
virus SIVcpz), which are again known to have varying
drug sensitivities (14,15). The DNA anti-RT aptamer
RT1t49 folds into a stem–loop structure and binds to
the template-primer cleft of RT (16). This aptamer has
proven to be synergistic with NRTIs (AZTTP
or ddCTP) but additive with NNRTIs (Nevirapine or
Efavirenz), at least in vitro (15).
Just as drug-resistant mutations can arise, aptamer-
resistant variants of HIV-1 RT have been shown to
occur. Two mutants (N255D and N265D) of HIV-1 RT
were found that were resistant to the DNA anti-RT apta-
mer RT1t49 (15). These two mutations did not promote
resistance to either NRTIs or NNRTIs, but did aﬀect the
majority of anti- RT aptamers being tested (17). Natural
variants of HIV-1 RT also show resistance to some apta-
mers; the substitution R277K that occurs in some RT
variants yields resistance against some RNA pseudoknot
aptamers (14).
Because sequence variants of RT evade some anti-RT
aptamers and additional sequence variants that would
defeat aptamers may arise, it would be useful to have
aptamers against speciﬁc RT variants. For example, we
ﬁnd that the canonical pseudoknot RNA anti-RT apta-
mers do not bind in vitro to HIV-1 RT variants resistant to
NRTIs, but that we can isolate novel aptamers that bind
to these drug-resistant variants. Moreover, our aptamers
can bind to novel epitopes on both the WT and mutant
proteins, ultimately allowing both broad and speciﬁc
detection of HIV-1 RT variants. Traditional antiretroviral
resistance assays detect either the phenotype (viral
replication) or the genotype (sequence) of HIV-1 RT (5).
Phenotyping assays directly and quantitatively measure
the drug resistance of HIV-1 RT and can be used with
plasma samples that have viral loads of about 500 HIV
RNA copies/ml. However, phenotyping assays are rela-
tively involved and hence expensive and slow, with a
turnaround time of about 2–4 weeks. Genotyping assays
have similar sensitivities and detection ranges, are less
expensive, and have turnaround times of <1 week (18).
However, genotyping requires a foreknowledge of drug-
resistant alleles, and the interpretation of how sets of
alleles map to resistance proﬁles may be nonobvious.
Even though these assays have been widely adopted in
standard HIV care, they are both laborious and expensive.
We believe that since our aptamers can speciﬁcally detect
puriﬁed HIV-1 RT in complex biological ﬂuids at concen-
trations as low as 1nM, they may prove useful in diag-
nostic methods such as aptamer-based microarrays (19,20)
both for directly typing HIV-1 RT drug-resistant variants
and for augmenting genotyping assays.
MATERIALS AND METHODS
HIV-1 RT preparation
Wild-type HIV-1 RT was purchased from Ambion
(Austin, TX) and Mutant 3 (M3) HIV-1 RT was prepared
as previously described with some minor modiﬁcations
(21). In short, the p51 subunit was cloned into the
vector pET30a (+) and the p66 subunit was cloned into
pET21a (+). The two subunits were expressed separately
in a BL21 (DE3) codon plus RIL Escherichia coli strain
(obtained from Novagen, Gibbstown, NJ). The heterodi-
meric M3 HIV-1 RT was puriﬁed on a DEAE-Sepharose
(Promega, Madison, WI) column followed by a Ni-aﬃnity
column (Qiagen, Valencia, CA). Pellets of p66 and p51
were resuspended in Buﬀer A [50mM Tris–HCl, pH 7.9,
60mM NaCl, 8% glycerol (v/v), and 1mM dithiothreitol
(DTT)] at a 4:1 molar ratio (four parts p66 to one part
p51) and pooled. Cells were disrupted using a ﬂow-
through, high-pressure homogenizer and then centrifuged
at 28000 g for 45min at 48C. Supernatants were loaded
onto DEAE-Sepharose columns equilibrated with Buﬀer
A. The gravity ﬂow-through was collected, pooled, sup-
plemented with NaCl to 500mM and imidazole to 10mM,
and then loaded onto Ni–NTA columns pre-equilibrated
with Buﬀer B [50mM Tris–HCl, pH 7.9, 500mM NaCl,
8% glycerol (v/v) and 1mM DTT] supplemented with
imidazole to 10mM. The columns were washed with 12
column volumes (CV) of Buﬀer B with additional NaCl to
1M, 12 CV of Buﬀer B with 5mM imidazole and 12 CV of
Buﬀer B with 10mM imidazole. RT was sequentially
eluted with single CV of Buﬀer B supplemented with
40mM, 60mM, 100mM and 200mM imidazole. Eluted
fractions were assayed for purity by SDS–PAGE.
Fractions were pooled according to purity (>97%) and
then dialyzed overnight into 2 Storage Buﬀer (50mM
Tris pH 7.5, 150mM NaCl, 20% glycerol and 1mM
DTT) using 3-ml Slide-a-lyzer dialysis cassettes (Pierce,
Rockford, IL) with a 3500 MWCO. RT samples were
frozen at –208C and used within 4–6 weeks, or frozen at
–808C for longer-term storage. Protein concentrations
were determined using a Bradford Assay (Bio-rad,
Hercules, CA).
In vitro selection
The DNA library for selection consisted of a 50-nt
random region ﬂanked by two primer sequences: 50-gata
atacgactcactatagggttacctaggtgtagatgct-N50-aagtgacgtctga
actgcttcgaa-30 (T7 RNA polymerase promoter is under-
lined). Some 10
13 DNA templates were transcribed
in vitro by T7 RNA polymerase to generate the initial
pool RNA (ca. 100 copies of each member of the pool).
After transcription, DNA templates were digested with
DNase and the transcripts were gel-puriﬁed and ethanol-
precipitated. A negative selection against the ﬁlter alone
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(200mM NaCl, 50mM Tris–HCl, pH 7.4, 10mM DTT
and 6mM MgCl2) and then passing it through 0.45mm
modiﬁed cellulose disks (Millipore, Bedford, MA).
M3 HIV-1 RT was added to the negatively selected
RNA pool at a ﬁnal concentration of 500nM in the ﬁrst
three rounds, 200nM for the next three rounds and 50nM
for the remaining rounds of selection. The binding reac-
tion was incubated at 258C for 10min and then ﬁltered
through 0.45mm modiﬁed cellulose disks. After washing
with 1ml Selection Buﬀer, bound species were eluted from
the modiﬁed cellulose membranes by incubating in
Elution Buﬀer (200mM NaCl, 25mM EDTA and 8M
urea) at 958C for 5min. Recovered RNA was reverse-
transcribed and PCR-ampliﬁed to generate DNA tem-
plates for the next round of selection. The selected pool
from round 12 was cloned and sequenced according to
standard procedures.
Doped selections were carried out under similar condi-
tions, except that the negative selection was against
WT HIV-1 RT. The concentrations of M3 and WT
HIV-1 RTs were 260nM for the ﬁrst round, 40nM for
the second round and 10nM for the last six rounds.
Aptamer secondary structuresand boundaries
The modiﬁcation of RNA with NMIA (N-methyl-isatoic
anhydride) and primer extension of modiﬁed RNA were
done as previously described for SHAPE (Selective
20-Hydroxyl Acylation and Primer Extension) (22). To
determine the 30-boundary of active M302, (50-
32P)-labeled
RNA was digested with 0.05U/ml of RNase T1 (Ambion,
Austin, TX) to generate a size marker [6min at 508Ci n
20mM NaAc (pH 5.2), 10mM EDTA and 1mg tRNA].
End-labeled RNA was also partially hydrolyzed (5min at
908C in 50mM NaHCO3 and 1mg tRNA) to generate
RNA fragments, which were EtOH-precipitated. A small
portion of the recovered RNA fragments was saved to
serve as an RNA fragment ladder. The rest was incubated
with 500nM of M3 HIV-1 RT for 10min at 258C. Active
RNA fragments were caught on modiﬁed cellulose and
separated from inactive ones. Recovered RNA fragments
from modiﬁed cellulose ﬁltration were fractionated on an
8% denaturing polyacrylamide gel along with the RNA
fragment ladder and RNase T1 marker. For 50-boundary
determination, (30-
32P)-labeled RNA was prepared by the
addition of an a-
32P ddATP to its 30-end by poly(A) poly-
merase. The 30-end-labeled RNA was then treated simi-
larly to the 50-end-labeled RNA described above. Based
on the boundary experiments and predicted RNA second-
ary structure, three shorter versions of M302 and 12.01
were designed and prepared by transcription from the T7
RNA polymerase phi 2.5 promoter on
foreshortened DNA templates. Since the phi 2.5 promoter
was used, all six transcripts began with AG and ended
with CU.
Binding constants and specificities
The dissociation constants of isolated aptamers were
determined by plotting the fraction of RNA bound to
the nitrocellulose ﬁlter as a function of protein concentra-
tion, using the following equation:
RNABound ¼
Bmax Protein ½ 
Kd þ Protein ½ 
,
where Bmax is the extrapolated maximal amount of
RNA:protein complex that will be bound. The binding
reaction was carried out by incubating 0.1nM (50-
32P)-
labeled RNA with 1, 3.2, 10, 32, 100, 320 and 1000nM
of protein in Selection Buﬀer for 10min at 258C. To sepa-
rate the RNA bound to protein from free RNA, the bind-
ing reaction was sieved through ﬁlters (Schleicher &
Schuell, Keene, NH) on a vacuum manifold. The ﬁrst
ﬁlter layer was nitrocellulose (top) and captured only
the RNA:protein complexes, while the second ﬁlter layer
was nylon (bottom) and captured all remaining RNA.
After washing with 1ml of Selection Buﬀer, nitrocellu-
lose and nylon ﬁlters were dried and visualized via a
Phosphorimager (GE Healthcare, Piscataway, NJ).
The dissociation constant of TPK1.1 was measured
under the same conditions that it was selected under
(RNA and protein were mixed and stored on ice for
30min and then transferred to 378C for 5min in
200mM KOAc, 50mM Tris–HCl, pH 7.7 and 10mM
DTT). Aptamers M302 and M302-S were labeled during
transcription with [a-
32P]-ATP (3000Ci/mmol, 10mCi/ml,
Perkin Elmer, Waltham, MA) and incubated separately
with 0.5mM of M3 HIV-1 RT, WT HIV-1 RT
(Ambion), AMV RT (Promega) or M-MLV RT
(Invitrogen, Carlsbad, CA) in Selection Buﬀer for 10min
at 258C.
Inhibition assays
RNA templates for reverse transcription=50 GGGGAA
UUGUGAGCGGAUAACAAUUCCCCUCUAGAAA
UAAUUUUGUUUAACUUUAAGAAGGAGAUAUA
CCAUGGGCAGCAGCCAUCAUCAUCAUCAUCAC
30 were transcribed from dsDNA which was ampliﬁed
from a PET28 vector (Invitrogen) with the following pri-
mers: forward primer=50 CGCGAAATTAATACGA
CTCACTATAGGGGAATTGTGAGCGG 30, and
reverse primer=50 GTGATGATGATGATGATGGC
TGCTGC 30. A stock template:primer mix (5X) was pre-
pared by denaturing 25nM 50-end-labeled reverse primer
and 125nM RNA template in Selection Buﬀer (minus
DTT) at 708C for 3min and slowly cooling (at 18C/s to
room temperature. The polymerase activity of WT and
M3 HIV-1 RTs was assayed by incubating a 5nM tem-
plate:primer mix with 50mM of dNTPs and RT (15, 50
and 500 nM) in Selection Buﬀer at 378C for 10min. As a
positive control for inhibitory activity, extension reactions
were performed in the presence of diﬀerent concentrations
of the TPK1.1 aptamer. Diﬀerent concentrations of apta-
mers (50 nM, 200nM and 1000 nM) were added to
the reactions containing 50nM of either WT or
M3 HIV-1 RT. Reactions were quenched by adding
20mM EDTA. cDNAs were separated from unextended
reverse primers by 8% PAGE and quantitated using
a Phosphorimager.
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plate:primer mix with RTs (15, 50 and 500 nM) in
Selection Buﬀer at 378C for 10min. The template:primer
mix for the RNase H assay was prepared similarly to that
described above except that 125nM unlabeled reverse
primer and 25nM 50-end-labeled RNA template were
used. Reactions were analyzed by gel electrophoresis and
quantitation, as with the polymerase assay.
Competitive binding assay
Competitions between unselected pool RNA, M302, 12.01
and TPK1.1 for HIV-1 RTs were carried out by mixing
100nM of M3 HIV-1 RT with 1mM of each unlabeled
RNA (pool RNA, M302, 12.01 and TPK1.1, respectively)
in Selection Buﬀer followed by the addition of  0.1nM of
(50-
32P)-labeled M302. The reaction was incubated for
10min at 258C. Binding assays of (50-
32P)-labeled 12.01
with M3 HIV-1 RT, (50-
32P)-labeled 12.01 with WT
HIV-1 RT and (50-
32P)-labeled TPK1.1 with WT HIV-1
RT were all carried out under the same
conditions. Protein-bound RNA and free RNA were
separated on a vacuum manifold, and visualized via a
Phosphorimager as described for the measurement of
aptamer dissociation constants.
Microarray analysis
Biotinlyated RNA was transcribed from templates
containing the T7 RNA polymerase phi 2.5 promoter
and biotin-AMP (Biotin-8; Adegenix, Monrovia, CA).
After puriﬁcation, biotinlyated RNA was resuspended in
Selection Buﬀer, heated to 708C for 3min and slowly
cooled to 258C. Glycerol was added to the samples to a
ﬁnal concentration of 5%. Biotinlyated RNA was printed
onto neutravidin-coated slides (Pierce) using a Manual
Glass Slide Microarrayer (V&P Scientiﬁc, San Diego,
CA) at 65–75% humidity, and the slides were incubated
for an additional 30min. The slides were then covered
with a 16-well Flexwell partitioning pad (Grace BioLabs,
Bend, OR) for the addition of solutions. The surface of the
neutravidin-coated slide was blocked with Blocking Buﬀer
[1  Selection Buﬀer with 1  Roche blocking buﬀer and
0.1% Tween-20 (Sigma Aldrich, St Louis, MO)] for
45min at room temperature. After rinsing three times
with 100ml Blocking Buﬀer, the samples were incubated
with 75ml of 1nM target protein suspended in Blocking
Buﬀer for 45min at room temperature. The wells were
rinsed six times with 100ml Blocking Buﬀer before appli-
cation of the primary antibody (100ml, 1:6000 dilution in
Blocking Buﬀer). After 2h incubation, the wells were
rinsed six times with 100ml Blocking Buﬀer. The second-
ary antibody (100ml, 2mg/ml in Blocking Buﬀer) was
applied to each well and incubated for 1h, followed
by six rinses with 100ml Blocking Buﬀer. The primary
antibody was an anti-HIV-1 RT polyclonal from rabbit,
obtained from Dr. Stuart Le Grice through the NIH
AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH. The secondary antibody
was a polyclonal Cy3-labled goat anti-rabbit IgG and was
purchased from Amersham Biosciences (Piscataway, NJ).
The slide was further rinsed sequentially with 40ml
of Blocking Buﬀer, Selection Buﬀer with 0.1% Tween-
20, and Selection Buﬀer in a 50ml conical tube for 5min
each with shaking. The Flexwell was peeled oﬀ and the
slide was spin-dried and gently dried with hot air. The
processed slide was then immediately scanned on a micro-
array scanner—GenePix 4000 B (Molecular Devices,
Sunnyvale, CA).
RESULTS AND DISCUSSION
In vitro selection ofaptamers that bind todrug-resistant
HIV-1 RT
An RNA library with a N50 random region was used as a
starting point for the isolation of aptamers that speciﬁ-
cally bind to a mutant HIV-1 RT, M3 from the panel of
12 prototypical multidrug-resistant HIV-1 RT clones (23;
mapped to the RT structure in Figure 1). This mutant RT
was found to be highly resistant to the nucleoside RT
inhibitor 3TC (Lamivudine) and moderately resistant to
AZT (Zidovudine), ABC (Abacavir), ddI (Didanosine),
d4T (Stavudine) and TDF (Tenofovir) (24). It contains
8-amino-acid substitutions relative to the WT. Among
them, M41L, D67N, L210W and T215Y belong to the
set of thymidine analog mutations (TAMs) and account
for the resistance to AZT (25,26). The E44D and the
V118I mutations are strongly associated with TAMs and
in combination with the mutations cited above confer dual
resistance to AZT and 3TC (27,28). The substitution
M184V evokes not only strong resistance to 3TC, but
also some loss of resistance to AZT (29–31).
Aptamer selection was carried out for 12 rounds via
ﬁltration of the protein-bound population on a modiﬁed
cellulose ﬁlter (32). The progress of the selection was mon-
itored every other round by assaying the amount of RNA
retained on the modiﬁed cellulose ﬁlter relative to the total
ﬁltered population. Binding species increased from 2% in
Round 0 to 17% in Round 10 and 19% in Round 12.
During the course of the selection, a negative selection
against the ﬁlter alone was included to insure that ﬁlter-
binding species were not enriched. Further selection
resulted in decreased pool binding aﬃnity to M3 HIV-1
RT. Thus the Round 12 population was used in further
analysis and diagnostic testing.
Some 29 clones from Round 12 were sequenced
(Figure 2a). Most of the sequences in the population
appeared to diﬀer substantively from one another except
for Aptamer 12.01, which was repeated ﬁve times. In order
to better identify common sequence motifs, we chose to
use the MEME server (http://meme.sdsc.edu), which dis-
covers motifs in groups of related DNA sequences using
statistical modeling techniques (33). No common sequence
motifs were found that could be used to subdivide the
population into sequence families.
An initial binding analysis showed that Apatmer 12.01
bound to both M3 and WT HIV-1 RTs with similar bind-
ing aﬃnities. In a further attempt to isolate aptamers that
would more speciﬁcally bind to M3 HIV-1 RT, a partially
randomized population centered on Aptamer 12.01 was
generated. This ‘doped’sequence pool contained 70%
WT residues and 30% non-WT residues (i.e. 70% G,
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1 CUUCCCUCCUCCACAAAUUAUUUUCUUUGACCACCCGCCCAUCGAACGCC 12.25
1 UAACAUAGUUGUCGAAGUCCUUUGUAAGUGGGCUUCCAUAGCUACCAUUU 12.22
1 AGCUCUGCUAUCUGGCGUACAAAUUUGCCCAUCGCCUCGUAGUUUCGUGC 12.21
1 GCAAAGUGAUACGUUAAGUCUUUUUAAUCACAUGUAUAGCUCACCCGCAU 12.24
1 CGCAGCUCCUUCCUCAUUCCAGAUUGUCGUAAUUCAUCCCAUUGCUCCCC 12.19
1 CGAUGCGCUUUGUACUACACAUAUGGACAGCUCACACCCCUUCGCCUU 12.18
1 UUUUUCACUCGCUCGUUUUUUAGCGCAACAUCAAAAUUGGUUGUCUCGGC 12.17
1 UCCACGAGCCAACAUGUUCUUUGCACAAUUAGUUCCACGCAUUCCUCUGU 12.16
1 ACGGCUGUUAGAAUGUGCCGUCACAAAGUAUAGGUUAGCGCGCCUGCAA 12.20
1 UACUCAAUUUCUCGAAGUUCUAAUUAAUUACAGACUCUCGCCGCAGCUUC 12.10
1 CACUUACACAAACCUGUAGUUUUAUGCUUCACAUAUCGCACAGGACGCUU 12.09
1 AUUCUUGUCUAUCUUUCAAAAUACCAAUUCUUGACGCCCAAUUACUCGCC 12.08
1 CAUAUCGGCGUGCAAUGACGCUCCUUAAACACCUCCGUUGACAUGGCCG 12.13
1 CAUGUGAGGCACUGAAGCUUAGAUUGUCGUUCCCCUUGGCCCAUCCAUAU 12.12
1 GAUAUUCGCAUUGGCUUCGUCUCAUUUUUAAAUUUUCUGCGGAUCGCAAGC 12.11
1 UUUUGCCCGGCUUGGCACAUUCAGAAGGGAACGGACUACCCGCGGUUCUGU 12.15
1 CACAAAUCUUACGCUGCGCCACUCCCCCCUGCCAAGCUUCAAAGUGGUG 12.14
1 AACUCAUUGGGAGUCGUGUAAAGCAUCCGCCCUUCCUUUCCUCACCGGCU 12.02
5 CUUCAGAUUCAUUUAUAAGAUCCGACAACCUGUCUAUUAGUUGCGCCGAUU 12.01
1 AGCCUGCAAAACUCUCAAUGUAGGUAUAGGCUAACAUUCCCGGGCGCUGC 12.04
1 AGUCCGCUGCUUAGCUCAUAAGUGUUUGCCCCUCCACAAUUCGCCAAAA 12.03
1 UAAGCUAAAAAUAACAAUAAAAUUAACAACUGACACCCGGUUCGAUCGUA 12.06
1 CGCAUACCUUCGCAUUCGCUGGCCCCUAUUUUUUAGCCUCGUACCUCAGU 12.05
1 AUAUUCUUACUCCUCUUUACGAAAGAUCUAUCUAAUAUCACUACGCGGC 12.07
Repeats Sequence Clone
1 UAAACAAUUCUAAUAAAAUCGCACUACUUCGGCAUCAAACCCAUCGAUGC 12.23
1 CUUCCCUCCUCCACAAAUUAUUUUCUUUGACCACCCGCCCAUCGAACGCC 12.25
1 UAACAUAGUUGUCGAAGUCCUUUGUAAGUGGGCUUCCAUAGCUACCAUUU 12.22
1 AGCUCUGCUAUCUGGCGUACAAAUUUGCCCAUCGCCUCGUAGUUUCGUGC 12.21
1 GCAAAGUGAUACGUUAAGUCUUUUUAAUCACAUGUAUAGCUCACCCGCAU 12.24
1 CGCAGCUCCUUCCUCAUUCCAGAUUGUCGUAAUUCAUCCCAUUGCUCCCC 12.19
1 CGAUGCGCUUUGUACUACACAUAUGGACAGCUCACACCCCUUCGCCUU 12.18
1 UUUUUCACUCGCUCGUUUUUUAGCGCAACAUCAAAAUUGGUUGUCUCGGC 12.17
1 UCCACGAGCCAACAUGUUCUUUGCACAAUUAGUUCCACGCAUUCCUCUGU 12.16
1 ACGGCUGUUAGAAUGUGCCGUCACAAAGUAUAGGUUAGCGCGCCUGCAA 12.20
1 UACUCAAUUUCUCGAAGUUCUAAUUAAUUACAGACUCUCGCCGCAGCUUC 12.10
1 CACUUACACAAACCUGUAGUUUUAUGCUUCACAUAUCGCACAGGACGCUU 12.09
1 AUUCUUGUCUAUCUUUCAAAAUACCAAUUCUUGACGCCCAAUUACUCGCC 12.08
1 CAUAUCGGCGUGCAAUGACGCUCCUUAAACACCUCCGUUGACAUGGCCG 12.13
1 CAUGUGAGGCACUGAAGCUUAGAUUGUCGUUCCCCUUGGCCCAUCCAUAU 12.12
1 GAUAUUCGCAUUGGCUUCGUCUCAUUUUUAAAUUUUCUGCGGAUCGCAAGC 12.11
1 UUUUGCCCGGCUUGGCACAUUCAGAAGGGAACGGACUACCCGCGGUUCUGU 12.15
1 CACAAAUCUUACGCUGCGCCACUCCCCCCUGCCAAGCUUCAAAGUGGUG 12.14
1 AACUCAUUGGGAGUCGUGUAAAGCAUCCGCCCUUCCUUUCCUCACCGGCU 12.02
5 CUUCAGAUUCAUUUAUAAGAUCCGACAACCUGUCUAUUAGUUGCGCCGAUU 12.01
1 AGCCUGCAAAACUCUCAAUGUAGGUAUAGGCUAACAUUCCCGGGCGCUGC 12.04
1 AGUCCGCUGCUUAGCUCAUAAGUGUUUGCCCCUCCACAAUUCGCCAAAA 12.03
1 UAAGCUAAAAAUAACAAUAAAAUUAACAACUGACACCCGGUUCGAUCGUA 12.06
1 CGCAUACCUUCGCAUUCGCUGGCCCCUAUUUUUUAGCCUCGUACCUCAGU 12.05
1 AUAUUCUUACUCCUCUUUACGAAAGAUCUAUCUAAUAUCACUACGCGGC 12.07
Repeats Sequence Cl
(a)( b)
one
1 UCAUGGGAUAAACUCGCCAUAAACAAUAAUUAUAAACAAAGACAUGGCAA M319
1 UGAUAAUUUGGUAUGCGACCCUCAUCCCUUAGCGUCUCUCGACUGAAUCC M318
1 UUACAACCAUAAAUUUUACCGCAUACGCCGCAUUUCCAACUGCUCUCAUC M317
1 UAAGAUAACUACGGCGAGUAAAACUAUAAAAAGAGUCGUAAGUCCUGUCUC M316
1 AUUUAUAUUAUGCAUUGCUGGUUUAUUUAGCUAUUGCAUAACCAUUGACA M322
1 ACUUUACAGCGUAGAGCGUUAUGUCCCGGUAAAUCAUCCAUAGCGACUCU M321
1 UAUUGCGCACUCAAAGGACGAAACCCGUACCUGUGCGCUGUAAAUUGUUC M320
1 UGAGAUAUCGUAAACGCUAAAUCUUCCUCGUGAAAGUUUGCAUCUCCUUC M310
1 UGGUAGGCACAUGUAUACCUCAGAUAGUUACAAGUCACACCCCGAGCGAC M309
1 AUCUCCAAAUUCCCUUAAGUACUUGCCCGAUAAAUUUGUUCGCCAUGGGU M308
1 AAUGAUAGUUAGUCAAGGUUCUGUCAGACAUCCUUGCAAGGGCCAGCUC M313
1 UGUGCUUGCCGGAUAUGGUUCAGAUUUCUUGAUAUGAAACACCCUUUGCC M312
1 AGACGUUUUGUGUUAGUCGCCGUCCAACGUCUUUCAGCUAAUUCAUCGAU M311
1 CUGAUGGAAUGUUCAUUUUCUGUAAUUAGAUGUGCGAGUGGCUGGCCAAUC M315
1 UAUUGCGCACUCAAAGGACGAAACCCGUACCUAUGCGCUGUAAAUUGUUC M314
4 CACUUACACAAACCUGUAGUUUUAUGCUUCACAUAUCGCACAGGACGCUU M302
4 CUUCAGAUUCAUUUAUAAGAUCCGACAACCUGUCUAUUAGUUGCGCCGAUU 12.01
1 UAACAUAGUUCUCGAAGUCCUUUGUAAGUGGGCUUCCAGAGCUACCAUUU M304
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1 UAACAUAGUUCUCGAAGCCCUUUGUAAGUGGGCUUCCAGAGCUACCAUUU M306
1 AUAGCAUUAAGCAUCGUCCUUUUACACACGCUUACAAGUUUGCGACCUCC M305
1 GCAAAGCGAUUAACACGCAUGUAUAGCUCCCACCCCAAUAUGCAGCGUUC M323
1 CACAUCCCAUUCAACCGGCGCUGGCAAUUUCUUCCCUACAGAUAUCGUGC M307
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2 GAUAUUCGCAUUGGCUUCGUCUCAUUUUUAAAUUUUCUGCGGAUCGCAAGC M303
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Repeats Sequence Clone
Figure 2. Sequences of aptamers binding to M3 HIV-1 RT. (a) Sequences from 29 clones isolated from the selected Round 12 pool that bound to M3
HIV-1 RT. The constant regions are not shown. The number of repeats of each sequence is shown to the right. (b) Sequences from 30 clones isolated
from the selected Round 8 doped Aptamer 12.01 pool that bound to M3 HIV-1 RT. Repeats are again indicated to the right. Sequence M302 from
the previous selection was found again in this selection, likely indicating a small amount of cross-contamination.
L M 41
M3 WT
Y T 215
W L 210
V M 184
I V 118
D T 69
N D 67
D E 44
L M 41
M3 WT
Figure 1. Drug resistance mutations in M3 HIV-1 RT. (a) Sequence substitutions of M3 (right) relative to WT (left). Numbers indicate position in
the amino acid sequence. (b) Sequence substitutions in M3 HIV-1 RT (pink) mapped onto the known 3D structure. The chain in blue is the WT
HIV-1 RT p66 subunit and the chain in magenta is the p51 subunit. A 33 residue, pseudoknot RNA aptamer that interacts with the RT template/
primer-binding site is shown in green. This image was generated through Protein Explorer using the 1hvu PDB ﬁle as a template.
Nucleic Acids Research, 2008, Vol. 36, No. 21 674310% A, 10% U and 10% C) at each originally random
sequence position. Eight additional rounds of selection
were carried out; in each round a negative selection
against WT HIV-1 RT was included, eﬀectively removing
as many WT binding species from the population as pos-
sible. The selection yield increased from 2% (Doped 12.01,
Round 0) to 25% (Round 8) for M3 HIV-1 RT and at the
same time from 1% (Doped 12.01, Round 0) to 10% for
WT HIV-1 RT (Round 8). It is interesting that despite the
negative selection that there was some residual aﬃnity for
the WT HIV-1 RT, indicating that the identiﬁcation of
aptamers that can discriminate based on the few muta-
tions that distinguish these proteins is a relatively diﬃcult
task. The binding aﬃnities of the Round 7 pool and
Round 8 pools were similar, and thus the selection was
considered to be complete.
A total of 30 clones from the selected, doped pool were
sequenced. The parental Aptamer 12.01 was found to
occur multiple (four) times, as did the Aptamer M302
(four times) and M303 (two times) (Figure 2b). Sequence
M302 was also present once in the previous selection,
indicating that it may have entered the selection as a con-
taminant. Again, no common sequence motifs were found
between any of the aptamers. Since no consensus families
or motifs were apparent, we carried out further analyses
with Aptamers 12.01 and M302, as these were the
sequences that were most prevalent in both selections.
Structural analyses ofselected aptamers
Many of the previously isolated RNA aptamers against
HIV-1 RT fold into pseudoknot structures (9,10).
Aptamers 12.01 and M302 are predicted to fold into
stem–loop structures (34) (Figure 3a and b). However,
since MFOLD cannot predict pseudoknot structures
with accuracy, we attempted to conﬁrm the predicted
structures using the SHAPE method (Figure 3c and d)
(22). In this method, the 20-hydroxyl groups of ﬂexible
nucleotides (for example, those in loop regions) can
react with NMIA to form a nucleotide 20-ester, which is
in turn revealed by primer extension. In contrast, nucleo-
tides in base-paired regions are frequently unreactive to
modiﬁcation. Since RT stops at the nucleotides just
prior to the 20-O-adduct (35), the bands from NMIA are
1nt oﬀ from the dideoxy sequencing ladder. In Figure 3,
the nucleotide positions are numbered according to the
NMIA lanes.
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Figure 3. Secondary structural analysis of aptamers. (a) Predicted secondary structure of Aptamer 12.01. Numbers are nucleotide positions relative to
the 50-end of the RNA (+1). The dots are nucleotides whose 20-hydroxyl groups are available for NMIA-modiﬁcation as revealed by SHAPE.
(b) Predicted secondary structure of Aptamer M302. Numbers and dots are the same as in (a). (c) Probing the secondary structure of Aptamer 12.01
using SHAPE. Lanes ‘U’, ‘C’, ‘G’ and ‘A’ are dideoxy-sequencing ladders. The lane marked as ‘+’ is transcription-mediated primer extension of
NIMA-modiﬁed Aptamer 12.01. Bands are oﬀset by 1nt compared to the sequencing ladder. Nucleotide positions corresponding 20-O-adduct
formation are numbered according to NMIA lanes and were marked in the predicted secondary structure for Aptamer 12.01, shown in (a). The
lane marked as ‘–’ is primer extension of unmodiﬁed Aptamer 12.01. (d) Probing the secondary structure of Aptamer M302 using SHAPE. Modiﬁed
positions were marked in the predicted secondary structure for Aptamer M302, shown in (b). Conventions are as in (c).
6744 Nucleic Acids Research, 2008, Vol. 36, No. 21Residues U38-A47, C52-A61 and C68-U72 of Aptamer
12.01 were predicted to fall outside of paired stem
structures, and were prone to NMIA modiﬁcation by
primer extension, largely conﬁrming the prediction of
Aptamer 12.01’s secondary structure. Chemical probing
by SHAPE of Aptamer M302 was also largely consistent
with the predicted structure, in that A30-A34, A41,
C49-A52 and A67-C71 were predicted to fall outside of
base-paired regions. Residues U43, U44, U58 and C59
were also unreactive, possibly because these residues are
involved in tertiary structural pairings or are otherwise
sterically hindered. However, it is also possible that
these residues are just continuation of the helix, since
tandem U-U base pairs and U-C base pairs are observed
in RNA crystal structures (36,37).
Boundary mapping experiments were also performed
with Aptamers M302 and 12.01. For 30-boundary map-
ping, (50-
32P)-labeled RNA was used. After partial alkaline
hydrolysis and binding to HIV-1 RT, functional RNA
fragments were isolated by ﬁltration, and the population
of functional fragments was analyzed by PAGE. There was
clearly a protein-binding 30-boundary at G75 of M302
(Figure 4a), and a 50-boundary was similarly mapped
to C23 using (30-
32P)-labeled RNA (data not shown).
A3 0-boundary (U77) for Aptamer 12.01 was determined,
but a 50-boundary could not be delineated. The minimal
requirements for Aptamer 12.01 were instead determined
by synthesizing foreshortened constructs.
To conﬁrm the boundaries of M302 and 12.01, minimal
versions of the aptamers were designed and synthesized.
Three more minimal versions of Aptamer M302 were con-
structed: M302-1, M302-2 and M302-S (Figure 4b) span
nucleotides 25–75, 24–76 and 23–77, respectively, of the
parental Aptamer M302, and also have AG substituted
for the ﬁrst two nucleotides and CU for the last two
nucleotides (these substitutions facilitate enzymatic incor-
poration of biotin, for later applications). A standard
binding assay (at 100nM of M3 HIV-1 RT) revealed
that all three foreshortened aptamers retained their activ-
ity, but that the longest aptamer, M302-S, had the best
binding. Minimal versions of Aptamer 12.01 [12.01-1
(residues 33–77), 12.01-2 (32–78), 12.01-3 (31–79), 12.01-4
(30–80) and 12.01-S (29–81)] were also constructed
(Figure 4c). Similar binding was observed for all ﬁve
constructs, although the longest construct again had
the best binding activity.
The aﬃnities of the minimal aptamers 12.01-S and
M302-S were also measured. As shown in Figure 4d,
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Figure 4. Engineering minimal aptamers. (a) Functional boundary determination for Aptamer M302. 30-boundaries were determined by binding
partially hydrolyzed, 50-end-labeled Aptamer M302 to M3 HIV-1 RT. Recovered RNA fragments were analyzed by PAGE (lane 2), along with
unreacted Aptamer M302 (lane 1), a partially hydrolyzed Aptamer M302 ladder (lane 3) and a G-ladder generated by nuclease T1 hydrolysis (lane 4).
G75 is the functional 30-boundary of Aptamer. (b) Predicted secondary structure of minimal Aptamer M302-S. (c) Predicted secondary structure of
minimal Aptamer 12.01-S.
Nucleic Acids Research, 2008, Vol. 36, No. 21 6745both shortened aptamers have decreased binding aﬃnities
compared with their parental sequences. The dissociation
constant of 12.01-S increased about 2-fold (from 70 to
120nM for binding to WT HIV-1 RT, and from 70 to
15nM for binding to M3 HIV-1 RT), while the dissocia-
tion constant of M302-S increased from 30 to 100nM for
M3 HIV-1 RT. The minimal M302-S variants had binding
speciﬁcities for M3 HIV-1 RT relative to WT HIV-1 RT
that were similar to the speciﬁcity of the longer, parental
aptamer (Figure 5).
We and others have shown that aptamers can have
extraordinary speciﬁcities for their targets. An aptamer
isolated against theophylline can discriminate against caf-
feine by a factor of over 1000, even though caﬀeine diﬀers
from theophylline by a single methyl group (38). Aptamers
that can bind to L-citrulline and L-arginine can discri-
minate between these two compounds and also their
D-isomers (39). Aptamers can also ﬁnely discriminate
between related proteins. An aptamer against the beta 2
isozyme of protein kinase C could readily distinguish it
from the highly related alpha isozyme (40). The aptamer
NX 1838 which was selected against the 165-amino-acid
form of vascular endothelial growth factor (VEGF165)
does not show any binding aﬃnity to VEGF 121, which
lacks exon 7 sequences (41). Finally, an anti-bFGF (basic
ﬁbroblast growth factor) aptamer discriminates against
other members of the related FGF family (42). Perhaps,
one of the best examples of aptamer discrimination
between proteins, though, is the ability of aptamers to
distinguish one species from another. An aptamer has
been shown to separate bovine factor IX from human
factor IX (43) Sullenger and co-workers (44) have actually
used ‘toggle selections’ between species to identify apta-
mers that speciﬁcally recognize homologous proteins from
one or another organism. An anti-porcine thrombin (FIIa)
aptamer bound porcine FIIa with a dissociation constant
of 50 8pM, but human FIIa with a dissociation constant
of >600 nM, a >10000-fold change in aﬃnity.
Specificities of anti-M3aptamers
The dissociation constants of Aptamers 12.01 and M302
were determined by measuring binding as a function of
protein concentration, for both M3 and WT HIV-1 RTs
(Figure 5a and b). Surprisingly, despite the fact that nega-
tive selection was employed and the ﬁnal pools appeared
to discriminate between the protein variants, Aptamer
12.01 had a binding constant of 70nM for both M3 and
WT HIV-1 RTs. In contrast, Aptamer M302 had a bind-
ing constant for M3 HIV-1 RT of 30 nM, but bound the
WT enzyme with an aﬃnity similar to that of the unse-
lected pool RNA (about 1mM, Figure 5c). As a positive
control, the dissociation constant of TPK1.1 for WT HIV-
1 RT was also measured. The reported dissociation con-
stant value is 5 nM, while we obtained a value of 14nM
(9); similar results were obtained both with our binding
buﬀer and with the binding buﬀer described therein.
TPK1.1 showed no binding above background to M3
HIV-1 RT (Figure 5d).
To further assess the speciﬁcity of M302, this aptamer
was incubated with either 0.5mM of M3 HIV-1 RT, WT
HIV-1 RT, AMV RT or M-MLV RT in Selection Buﬀer.
Of course, because AMV RT was used to reverse tran-
scribe RNA to cDNA during the selection process, iso-
lated aptamers should not be able to strongly bind to
AMV RT. As shown in Figure 6, M302 speciﬁcally
binds to M3 HIV-1 RT relative to RTs from other species
of RTs. Such speciﬁcity has previously been demonstrated
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Figure 5. Dissociation constants of anti-HIV-1 RT aptamers. (a) Binding curve of Aptamer 12.01 to M3 (squares) and WT (dots) HIV-1 RTs.
(b) Binding curve of Aptamer M302 to M3 (squares) and WT (dots) HIV-1 RTs. (c) Binding curve of unselected pool RNA to M3 (squares) and WT
(dots) HIV-1 RTs. (d) Summary of aptamers’ binding constants (at 258C) and inhibition constants (at 378C). All values are in nanomolar.
6746 Nucleic Acids Research, 2008, Vol. 36, No. 21for aptamers selected against HIV-1 RT, M-MLV RT and
AMV RT (9,45).
In order to determine whether the aptamers might even-
tually be useful for in vivo applications, binding assays of
isolated aptamers were also performed at 378C and gave
similar results. This is perhaps not surprising for TPK1.1,
as it had been selected under a regime where it saw both
48C and 378C incubations (9), and had also been shown to
form competent complexes with RT at room temperature
(46). However, our aptamers have previously only been
selected and assayed at ambient temperature, and thus it
is interesting that they maintained performance at higher
temperatures.
Aptamers bind butdo notinhibit RTs
Wild-type HIV-1 RT has both DNA polymerase activity
and RNase H activity. M3 HIV-1 RT has polymerase
activity that is comparable to WT HIV-1 RT
(Figure 7a), but has lost most of its RNase H activity
(Figure 7b). This was somewhat unexpected since the
amino acid substitutions in M3 were in the polymerase
but not the RNase H domain. However, it is known
that mutations in the polymerase domain can aﬀect
RNase H activity by aﬀecting the position of the tem-
plate-primer or the structure of the RNase H domain
itself (47). The abilities of selected aptamers to inhibit
the DNA polymerase activity of M3 and WT HIV-1
RTs were assayed at 378C. Neither the aptamers nor unse-
lected pool RNA was able to signiﬁcantly inhibit the
[HIV-1RT](nM) 0 15 50 500 15 50 500
WT M3
0 15 50 500 15 50 500
WT M3
Template
After digestion
[HIV-1 RT] (nM)
(a)
(b)
(c)
(d)
Primer
Extended cDNA
[Aptamer] (nM)
Primer
Extended cDNA
Primer
Extended cDNA
R
T
 
(
W
T
)
R
T
 
(
M
3
)
Aptamer
Aptamer M302 12.01 Pool TPK 1.1
M302 12.01 Pool TPK 1.1
Template
After digestion
R
N
a
s
e
H
 
(
W
T
)
[Aptamer] (nM) 50
200
1000
50
200
1000
50
200
1000
50
200
1000
0
50
200
1000
50
200
1000
50
200
1000
50
200
1000
0
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Nucleic Acids Research, 2008, Vol. 36, No. 21 6747extension of a (50-
32P)-labeled primer up to concentrations
of 1mM. In contrast and as a positive control, TPK1.1
readily inhibited primer extension, as has been previously
described (9). Similarly, the selected aptamers did not
inhibit the RNase H activity of WT HIV-1 RT, although
TPK1.1 again showed strong inhibition (Figure 7c) (14).
Anti-M3aptamers recognizeaunique epitope on HIV-1 RT
The fact that our selected aptamers bound but did not
inhibit HIV-1 RTs suggested that they might bind in a
diﬀerent way or at a diﬀerent site than the canonical pseu-
doknot aptamers that have previously been discovered.
In order to determine whether the various aptamers
were binding diﬀerent protein epitopes, we carried out
competitive binding assays. As can be seen in Figure 8,
each of the aptamers 12.01 and M302 inhibits binding of
the other to M3 HIV-1 RT. It is likely this is not due to
interactions between the two RNAs, since M302 does not
interfere with the binding of 12.01 to WT HIV-1 RT. In
contrast, Aptamer 12.01 and TPK1.1 do not compete for
binding to WT HIV-1 RT. These results are consistent
with the activity assays described above, since TPK1.1
has been shown to bind to the template-primer binding
site of WT HIV-1 RT (13,46,48,49) The simplest explana-
tion of these results is that the binding sites for 12.01 and
M302 on HIV-1 RTs are remote from the template-primer
binding site. To our knowledge, this is the ﬁrst pair of
aptamers that recognize and bind to diﬀerent epitopes
on HIV-1 RT. Indeed, there have previously been only a
few selections yielding aptamers that bound to more than
one epitope on any protein (44,50–53).
Given that a number of previous selections have pro-
duced pseudoknot aptamers that bind to the template-
primer binding site of HIV-1 RT, it is interesting that
our selection produced a compact hairpin structure that
bound to diﬀerent, non-overlapping epitopes on the
viral protein. The amino acid substitutions in M3 HIV-1
RT may impede binding of the canonical pseudoknot
aptamer (TPK1.1) to RT’s template-primer binding site,
perhaps due to a conformational change in this site, and
would similarly have made it less likely for this structure
to be selected. In contrast, these substitutions might make
a diﬀerent epitope even more attractive during selection.
For Aptamer M302, it is possible that the 8-amino-acid
diﬀerence between WT and M3 HIV-1 RT induced a con-
formational change that yielded a M3-speciﬁc epitope that
was readily recognized by RNA.
The recognition of a conformation-speciﬁc epitope is
consistent with what is known of HIV-1 RT enzymology.
Most of the TAMs are in the neighborhood of incoming
nucleotides. These mutations may induce conformational
changes in the dNTP-binding site and alter interactions
with the 30-azido group of AZT, thereby enhancing its
excision (54). Substitutions that are not immediately adja-
cent to the nucleotide, such as M41L, may reinforce these
conformational changes. In fact, treatment of HIV-1
infected patients with AZT induces two distinct patterns
of resistance mutations. M3 HIV-1 RT contains the
TAM-1 cluster, and also D67N, K70R, T215F and
K219Q, some of which are representative of the TAM-2
cluster (55–57). While the structure of an AZT resistant
RT with a TAM-2 cluster revealed that one or both of the
substitutions T215F and K219Q might have induced long-
range conformational changes in the RT active site, the
crystal structure of RTs containing the M184V mutation
either in the absence or in the presence of M41L
and T215Y showed the polymerase active site had essen-
tially the same conformation as did WT HIV-1 RT (58).
However, the other substitutions found in M3 might cause
conformational changes that could lead to rejection of
TPK 1.1 or other aptamers from the template-primer-
binding site. Indeed, it has been suggested that M184V
and other amino acid residues involved in resistance to
NRTI might aﬀect the positioning or conformation of
the template-primer (31,59).
The conformational epitope that is revealed on M3
HIV-1 RT may be very similar to one already found on
the WT HIV-1 RT, since Aptamer M302 apparently
recognizes a similar or overlapping epitope to that recog-
nized by Aptamer 12.01 on both M3 and the WT protein.
The RNase H domain is another possible binding site
for aptamers, although to date aptamers directed solely
against this portion have bound weakly (8,60,61).
However, since Aptamer 12.01 does not inhibit the
RNase H activity of WT HIV-1 RT, it is less likely that
both Aptamers 12.01 and M302 bind to the RNase H
domain.
Anti-M3aptamerscanbeusedinmicroarray-basedsandwich
assays
Aptamers have previously been adapted to a variety of
assay formats for protein detection, including diﬀerent
types of sandwich assays (62). For sandwich assays,
immobilized aptamers [anti-PDGF, anti-thrombin, anti-
bFGF, anti-VEGF and anti-MUC1 (63)] capture target
proteins which are in turn detected with either antibodies
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Figure 8. Competitive binding of aptamers to M3 and WT HIV-1 RTs.
Aptamers M302, 12.01, TPK1.1 and the unselected pool RNA (N50)
were end-labeled (all at 0.1 nM, indicated on x-axis) competed with
diﬀerent cold versions of the same RNAs (all at 1000 nM, indicated in
inset) in the presence of either M3 or WT RT (indicated on x-axis).
Bound, radiolabeled RNA was collected by ﬁltration and quantitated.
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aptamer format has been demonstrated for the protein
dimer PDGF (64). Given that we have selected aptamers
appear to have diﬀerent binding speciﬁcity to closely
related WT and M3 HIV-1 RTs, we wished to see if this
property would also hold true in a facile sandwich assay.
In order to assess this hypothesis, we reampliﬁed the DNA
templates of M302, 12.01, TPK1.1 and the N50 pool using
primers containing a T7 RNA polymerase phi 2.5 promo-
ter, which replaces the initiating G with A. Using the
reconstructed DNA templates, we initiated transcription
with biotin-AMP (65). The yield of biotinylated aptamers
was about 40% by streptavidin gel-shift assay. 50-biotin-
lyated RNA was immobilized onto neutravidin-coated
slides and incubated with either WT or M3 HIV-1 RTs.
After washing, an anti-HIV-1 RT primary antibody from
rabbit and Cy3-labeled anti-rabbit IgG secondary anti-
body were sequentially applied to detect captured proteins
on the array.
Using this sandwich assay, we found we could sensi-
tively detect M3 and WT HIV-1 RTs spiked into complex
biological ﬂuids (Blocking Buﬀer) at concentrations as low
as 1nM (Figure 9). The speciﬁcities available with our and
others’ selected aptamers led to speciﬁc identiﬁcation of
the protein variants, with Aptamer M302 detecting only
M3 HIV-1 RT, TPK1.1 detecting only WT HIV-1 RT,
and Aptamer 12.01 detecting both. While optimization
of these arrays will be necessary for quantitative determi-
nation of RT, further expansion of the number of apta-
mers that recognize drug-resistant RT variants could lead
to the development of protein-detection arrays that could
ﬁnely discriminate between the shapes of diﬀerent RT var-
iants. This would open the way to using aptamers for
directly screening for drug resistance, including by aug-
menting current genotyping assays. That said, we recog-
nize that it is an open question whether or not aptamers
can not only discriminate based on shape, but can also
classify based on shape. This is an interesting question
that we hope to resolve into the future.
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